718 related articles for article (PubMed ID: 31630436)
21. Twenty-four-week interim analysis from a phase 3 open-label trial of adalimumab in Japanese patients with moderate to severe hidradenitis suppurativa.
Morita A; Takahashi H; Ozawa K; Imafuku S; Nakama T; Takahashi K; Matsuyama T; Okubo Y; Kitamura S; Matsuda N; Zhao Y; Yokoyama M; Hayashi N; Terui T
J Dermatol; 2019 Sep; 46(9):745-751. PubMed ID: 31282051
[TBL] [Abstract][Full Text] [Related]
22. Impact of Single Nucleotide Polymorphisms of the Promoter of the TNF Gene on Adalimumab Treatment Responses in Hidradenitis Suppurativa.
Argyropoulou M; Trigoni A; Kaffenberger J; Stergianou D; Damoraki G; Mingiani E; Micha S; Krispinsky A; Meltzanidou P; Kanni T; Lazaridou E; Giamarellos-Bourboulis EJ
Dermatology; 2023; 239(5):746-752. PubMed ID: 37331331
[TBL] [Abstract][Full Text] [Related]
23. Adalimumab Dose Intensification in Recalcitrant Hidradenitis Suppurativa/Acne Inversa.
Zouboulis CC; Hansen H; Caposiena Caro RD; Damiani G; Delorme I; Pascual JC; Reguiai Z; Trigoni A; Vilarrasa E; Alfageme Roldán F
Dermatology; 2020; 236(1):25-30. PubMed ID: 31630144
[TBL] [Abstract][Full Text] [Related]
24. External Validation of the IHS4-55 in a European Antibiotic-Treated Hidradenitis Suppurativa Cohort.
van Straalen KR; Tzellos T; Alavi A; Benhadou F; Cuenca-Barrales C; Daxhelet M; Daoud M; Efthymiou O; Giamarellos-Bourboulis EJ; Guillem P; Gulliver W; Jemec GBE; Katoulis A; Koenig A; Lazaridou E; Lowes MA; Marzano AV; Matusiak L; Molina-Leyva A; Moltrasio C; Pinter A; Potenza C; Prens EP; Romaní J; Saunte DM; Sayed C; Skroza N; Stergianou D; Szepietowski JC; Trigoni A; Vilarrasa E; Kyrgidis A; Zouboulis CC; van der Zee HH
Dermatology; 2023; 239(3):362-367. PubMed ID: 36630943
[TBL] [Abstract][Full Text] [Related]
25. Evidence for a 'window of opportunity' in hidradenitis suppurativa treated with adalimumab: a retrospective, real-life multicentre cohort study.
Marzano AV; Genovese G; Casazza G; Moltrasio C; Dapavo P; Micali G; Sirna R; Gisondi P; Patrizi A; Dini V; Bianchini D; Bianchi L; Fania L; Prignano F; Offidani A; Atzori L; Bettoli V; Cannavò SP; Venturini M; Bongiorno MR; Costanzo A; Fabbrocini G; Peris K
Br J Dermatol; 2021 Jan; 184(1):133-140. PubMed ID: 32119111
[TBL] [Abstract][Full Text] [Related]
26. Lymecycline vs. clindamycin plus rifampicin in hidradenitis suppurativa treatment: clinical and ultrasonography evaluation.
Caposiena Caro RD; Molinelli E; Brisigotti V; Offidani A; Bianchi L
Clin Exp Dermatol; 2021 Jan; 46(1):96-102. PubMed ID: 32683727
[TBL] [Abstract][Full Text] [Related]
27. Improved clinical effectiveness of adalimumab when initiated with clindamycin and rifampicin in hidradenitis suppurativa.
Aarts P; van Huijstee JC; van der Zee HH; van Straalen KR; Prens EP
J Eur Acad Dermatol Venereol; 2024 May; 38(5):904-909. PubMed ID: 38112226
[TBL] [Abstract][Full Text] [Related]
28. Clindamycin versus clindamycin plus rifampicin in hidradenitis suppurativa treatment: Clinical and ultrasound observations.
Caposiena Caro RD; Cannizzaro MV; Botti E; Di Raimondo C; Di Matteo E; Gaziano R; Bianchi L
J Am Acad Dermatol; 2019 May; 80(5):1314-1321. PubMed ID: 30502416
[TBL] [Abstract][Full Text] [Related]
29. Reduction in pain scores and improvement in depressive symptoms in patients with hidradenitis suppurativa treated with adalimumab in a phase 2, randomized, placebo-controlled trial.
Scheinfeld N; Sundaram M; Teixeira H; Gu Y; Okun M
Dermatol Online J; 2016 Mar; 22(3):. PubMed ID: 27136622
[TBL] [Abstract][Full Text] [Related]
30. Adalimumab: A Review in Hidradenitis Suppurativa.
Kim ES; Garnock-Jones KP; Keam SJ
Am J Clin Dermatol; 2016 Oct; 17(5):545-552. PubMed ID: 27665300
[TBL] [Abstract][Full Text] [Related]
31. Long-term successful adalimumab therapy in severe hidradenitis suppurativa.
Blanco R; Martínez-Taboada VM; Villa I; González-Vela MC; Fernández-Llaca H; Agudo M; González-López MA
Arch Dermatol; 2009 May; 145(5):580-4. PubMed ID: 19451504
[TBL] [Abstract][Full Text] [Related]
32. Adalimumab medium-term dosing strategy in moderate-to-severe hidradenitis suppurativa: integrated results from the phase III randomized placebo-controlled PIONEER trials.
Jemec GBE; Okun MM; Forman SB; Gulliver WPF; Prens EP; Mrowietz U; Armstrong AW; Geng Z; Gu Y; Williams DA; Teixeira HD; Kimball AB
Br J Dermatol; 2019 Nov; 181(5):967-975. PubMed ID: 30916379
[TBL] [Abstract][Full Text] [Related]
33. Guselkumab for hidradenitis suppurativa: a phase II, open-label, mode-of-action study.
Dudink K; Bouwman K; Chen Y; DePrimo SE; Munoz-Elias EJ; Aarts P; Schappin R; Florencia EF; van Heeswijk B; Prens LM; van der Zee HH; Prens EP; van Straalen KR; Horváth B
Br J Dermatol; 2023 Apr; 188(5):601-609. PubMed ID: 36811949
[TBL] [Abstract][Full Text] [Related]
34. Real-world safety and effectiveness of adalimumab in patients with hidradenitis suppurativa: A 52-week analysis of a postmarketing surveillance study in Japan.
Hayashi N; Hayama K; Takahashi K; Kurokawa I; Okazaki M; Kashiwagi T; Iwashita E; Terui T
J Dermatol; 2023 Aug; 50(8):1034-1044. PubMed ID: 37264993
[TBL] [Abstract][Full Text] [Related]
35. Seven years-experience of adalimumab therapy for Hidradenitis Suppurativa in a real-life dermatologic setting.
Odorici G; Pacetti L; Forconi R; Schettini N; Zedde P; Corazza M; Bettoli V
J Dermatolog Treat; 2022 Jun; 33(4):2063-2067. PubMed ID: 33843413
[TBL] [Abstract][Full Text] [Related]
36. Development and validation of the International Hidradenitis Suppurativa Severity Score System (IHS4), a novel dynamic scoring system to assess HS severity.
Zouboulis CC; Tzellos T; Kyrgidis A; Jemec GBE; Bechara FG; Giamarellos-Bourboulis EJ; Ingram JR; Kanni T; Karagiannidis I; Martorell A; Matusiak Ł; Pinter A; Prens EP; Presser D; Schneider-Burrus S; von Stebut E; Szepietowski JC; van der Zee HH; Wilden SM; Sabat R;
Br J Dermatol; 2017 Nov; 177(5):1401-1409. PubMed ID: 28636793
[TBL] [Abstract][Full Text] [Related]
37. Clinical selection criteria in new clinical trials of hidradenitis suppurativa: External validity and implications on the daily clinical practice.
Montero-Vilchez T; Salvador-Rodriguez L; Sanchez-Diaz M; Cuenca-Barrales C; Martinez-Lopez A; Arias-Santiago S; Molina-Leyva A
Dermatol Ther; 2020 Nov; 33(6):e14254. PubMed ID: 32860480
[TBL] [Abstract][Full Text] [Related]
38. Adalimumab treatment for hidradenitis suppurativa associated with Crohn's disease.
Diamantova D; Lomickova I; Cetkovska P
Acta Dermatovenerol Croat; 2014; 22(4):291-3. PubMed ID: 25580790
[TBL] [Abstract][Full Text] [Related]
39. Secukinumab in patients with moderate-to-severe hidradenitis suppurativa based on prior biologic exposure: an efficacy and safety analysis from the SUNSHINE and SUNRISE phase III trials.
Zouboulis CC; Passeron T; Pariser D; Wozniak MB; Li X; Uhlmann L; Lobach I; Martinez AL; Ravichandran S; Alarcon I; Offidani A; Alam MS; Mendes-Bastos P
Br J Dermatol; 2024 May; 190(6):836-845. PubMed ID: 38470171
[TBL] [Abstract][Full Text] [Related]
40. Ustekinumab with Intravenous Infusion: Results in Hidradenitis Suppurativa.
Romaní J; Vilarrasa E; Martorell A; Fuertes I; Ciudad C; Molina-Leyva A
Dermatology; 2020; 236(1):21-24. PubMed ID: 31288233
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
